15 September 2026
Pay-for-delay: the CJEU confirms Teva/Cephalon and defines the limits of patent settlement agreements
11 September 2026
La saisie-contrefaçon, l’arme française que les titulaires étrangers oublient
10 September 2026
The launch letter before the UPC: what generics and biosimilars should write to avoid creating urgency
5 September 2026
Portfolio strategy and the UPC: where the value of life sciences assets lies
5 September 2026
Merz v. Viatris on appeal: urgency remains decisive, but not every signal is urgent
4 September 2026
UPC and life sciences: the first strategic lessons
3 September 2026
Imminent infringement before the UPC: the new geography of pharmaceutical risk
30 July 2024
Sanofi v. Amgen: the UPC's first revocation action and therapeutic antibody patentability, from revocation to reversal
25 July 2023
APIXABAN case in France: priority to the patent holder
26 October 2020
PEMETREXED patent infringement in France: €28 million in damages for Eli Lilly (“France is back”?)